To evaluate the clinical efficacy and safety of Bailing capsule in the treatment of patients with chronic kidney disease stage 2-4 (CKD stage 2-4)

Zhongda Hospital affiliated to Southeast University0 个研究点开始时间: 待定最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•1. The initial diagnosis met the western diagnostic criteria for chronic kidney disease: chronic kidney structure and dysfunction or decreased glomerular filtration rate (GFR) caused by various reasons for more than 3 months; Renal injury included: (1) proteinuria: urinary albumin excretion rate (UAER) = 30 mg/24 h; Urinary albumin-to-creatinine ratio (ACR) = 30 mg/g (=3 mg/mmol), (2) abnormal urinary sediment, (3) electrolyte and other abnormalities caused by renal tubular dysfunction, (4) histological abnormalities, (5) abnormal imaging examination, (5) abnormal renal function. (6) History of renal transplantation.
•2. CKD stage 2 (GFR=60 ml/min/1.73 m2, and GFR < 90ml/min/1.73 m2) or CKD stage 3 (GFR=30 ml/min/1.73 m2, GFR=30 ml/min/1.73 m2; GFR < 60ml/min/1.73 m2) or CKD stage 4 (GFR=15 ml/min/1.73 m2 and GFR < 30ml/min/1.73 m2);
•(3) The first visit time is 2017-1-1 to 2022-6-30, and the age is 18 years old and above.

•1. Patients who used other Chinese patent medicine of cordyceps sinensis from 2017-1-1 to 2022-6-30;
•(2) patients who underwent dialysis less than 3 months after the first diagnosis of CKD2-4 or CKD
•Patients with extended;
•3. Diagnose patients not associated with chronic kidney disease or chronic renal insufficiency.
•4. Inability to judge the efficacy or incomplete data affecting the efficacy or safety judgment.

发起方

Zhongda Hospital affiliated to Southeast University